Company Overview and News
NEW YORK (AP) — A federal appeals panel seems poised to reinstate a defamation lawsuit Sarah Palin brought against The New York Times after hearing oral arguments Friday.
Deputy Attorney General Rod Rosenstein suggested secretly recording President Donald Trump and discussed recruiting cabinet members to invoke the 25th Amendment to remove him, the New York Times reported Friday.
Deputy Attorney General Rod Rosenstein suggested last year he secretly record President Donald Trump in the White House, the New York Times reported, and also discussed recruiting cabinet members to invoke the 25th Amendment to remove Trump from office. The Times' report said Rosenstein made these suggestions in the spring of 2017, when Trump's firing of then-FBI Director James Comey put the White House into turmoil.
Jack Ma, the pioneer of China's internet industry, has termed the speculation swirling around his retirement as a "sea gossip", saying that he would rather die on the beach than in his executive office at Alibaba.
The Klown Kar Kavanaugh Karavan Keeps Kavorting through Washington, trying to salvage the Supreme Court seat for a nominee whose primary work experience, before becoming a federal judge, was working for the discredited independent-counsel investigation of President Bill Clinton and the discredited White House of George W. Bush.
In spite of The New York Times Company’s (NYT - Free Report) concerted efforts to lower its dependency on traditional advertising and focus on digitalization, shares of this news and information provider have tumbled roughly 12.7% compared with the industry’s decline of 12% in the past three months. Analysts pointed that fall in advertising revenue both in print and digital coupled with sluggish growth in paid digital subscriber base during the second quarter of 2018 impacted the stock’s performance.
NWDVW MNI NYTAB NEWM
Protesters opposed to President Donald Trump's Supreme Court nominee, Brett Kavanaugh, demonstrate in the Hart Senate Office Building on Capitol Hill in Washington, Thursday, Sept. 20, 2018. (AP Photo/J. Scott Applewhite)
After a lavish engagement galore of Mukesh and Nita Ambani’s eldest son Akash with Shloka Mehta it is time for Isha and Anand Piramal to steal the limelight with their fairy-tale romance. Apparently, the couple have opted for an exotic location for their engagement ceremony.
Washington: Nikki Haley, the US Ambassador to the UN, on Thursday slammed The New York Times for publishing a wrong story about expensive curtains at her official residence despite knowing the actual facts.
Sept 21 (Reuters) - The following are the top stories on the New York Times business pages. Reuters has not verified these stories and does not vouch for their accuracy.
Michael Cohen, President Donald Trump’s former lawyer, has met multiple times with special counsel Robert Mueller’s investigators, including within the past month, according to people familiar with the matter.
When Supreme Court nominee Brett Kavanaugh was part of Ken Starr’s team investigating Bill Clinton, some Americans wondered how they could explain President Clinton’s behavior to children. That was a reasonable question to ask.
COPENHAGEN — When a whistle-blower alleged that employees of a branch of the Danish lender Danske Bank had been knowingly working with customers who had broken the law, it was not the first time that questions had been raised about that particular office. It would not be the last.
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET